Skip to main content
SpringerLink
Log in

Cardiovascular Effects of Cancer Therapy

  • Chapter
Book cover Survivors of Childhood and Adolescent Cancer

Part of the book series: Pediatric Oncology ((PEDIATRICO))

This is a preview of subscription content, log in via an institution to check access.

Access this chapter

Log in via an institution
Chapter
USD 29.95
Price excludes VAT (USA)
  • Available as PDF
  • Read on any device
  • Instant download
  • Own it forever
eBook
USD 189.00
Price excludes VAT (USA)
  • Available as PDF
  • Read on any device
  • Instant download
  • Own it forever

Tax calculation will be finalised at checkout

Purchases are for personal use only

Institutional subscriptions

Preview

Unable to display preview. Download preview PDF.

Unable to display preview. Download preview PDF.

References

  1. Mertens AC, Yasui Y, Neglia JP et al. (2001) Late mortality experience in 5-year survivors of childhood and adolescent cancer: the Childhood Cancer Survivor Study. J Clin Oncol 19:3163–3172

    PubMed  Google Scholar 

  2. Moller TR, Garwicz S, Barlow L et al. (2001) Decreasing late mortality among five-year survivors of cancer in childhood and adolescence: a population-based study in the Nordic countries. J Clin Oncol 19:3173–3181

    PubMed  Google Scholar 

  3. Clark EB (1990) Growth, morphogenesis, and function: the dynamics of heart development. In: Moller JH, Neal WA, Lock JE (eds) Fetal, neonatal, and infant heart disease. Appleton-Century-Crofts, New York

    Google Scholar 

  4. Clark EB (1989) Effect of increased ventricular pressure on ventricular growth in stage 21 chick embryo. Am J Physiol 257:1455–1461

    Google Scholar 

  5. Fishman NH et al. (1978) Models of congenital heart disease in fetal lambs. Circulation 58:354–364

    PubMed  Google Scholar 

  6. Kim DH et al. (1989) Doxorubicin-induced calcium release from cardiac sarcoplasmic reticulum vesicles. J Mol Cell Cardiol 21:433–436

    Article  PubMed  Google Scholar 

  7. Pratt CB, Ransom JL, Evans WE (1978) Age-related Adriamycin cardiotoxicity in children. Cancer Treat Rep 62:1381–1385

    PubMed  Google Scholar 

  8. Billingham ME, Bristow MR, Glatstein E et al. (1977) Adriamycin cardiotoxicity: endomyocardial biopsy evidence of enhancement by irradiation. Am J Surg Pathol 1:17–23

    PubMed  Google Scholar 

  9. Billingham ME et al. (1978) Anthracycline cardiomyopathy monitored by morphologic changes. Cancer Treat Rep 62:865–872

    PubMed  Google Scholar 

  10. Ewer MS et al. (1984) A comparison of cardiac biopsy grades and ejection fraction estimations in patients receiving Adriamycin. J Clin Oncol 2:112–117

    PubMed  Google Scholar 

  11. Lipshultz SE, Colan SD, Gelber RD et al. (1991) Late cardiac effects of doxorubicin therapy for acute lymphoblastic leukemia in childhood. N Engl J Med 324:808–815

    PubMed  Google Scholar 

  12. Braverman AC et al. (1991) Cyclophosphamide cardiotoxicity in bone marrow transplantation: a prospective evaluation of new dosing regimens. J Clin Oncol 9:1215–1223

    PubMed  Google Scholar 

  13. Mills BA, Roberts RW (1979) Cyclophosphamide-induced cardiomyopathy. Cancer 43:223–226

    Google Scholar 

  14. Gottdiener JS et al. (1981) Cardiotoxicity associated with high dose cyclophosphamide therapy. Arch Intern Med 141:753–763

    Article  PubMed  Google Scholar 

  15. O'Connell TX, Berenbaum MC (1974) Cardiac and pulmonary effects of high doses of cyclophosphamide and isophosphamide. Cancer Res 34:1586–1691

    PubMed  Google Scholar 

  16. Watts RG (1991) Severe and fatal anthracycline cardiotoxicity at cumulative doses below 400 mg/m2: evidence for enhanced toxicity with multiagent chemotherapy. Am J Hematol 36:217–218

    PubMed  Google Scholar 

  17. Friedman HS et al. (1990) Glutathione protects cardiac and skeletal muscle from cyclophosphamide-induced toxicity. Cancer Res 50:2455–2462

    PubMed  Google Scholar 

  18. Simbre VC, Adams MJ, Deshpande SS et al. (2001) Cardiomyopathy caused by antineoplastic therapies. Curr Treat Options Cardiovasc Med 3:493–505

    PubMed  Google Scholar 

  19. Pai VB, Nahata MC (2000) Cardiotoxicity of chemotherapeutic agents. Drug Safety 22:263–302

    PubMed  Google Scholar 

  20. Leach J (1943) Effect of roentgen therapy on the heart. Arch Intern Med 72:715–745

    Google Scholar 

  21. Stewart JR, Fajardo LF (1984) Radiation-induced heart disease: an update. Prog Cardiovasc Dis 27:173–194

    Article  PubMed  Google Scholar 

  22. Stewart JR, Fajardo LF, Gillette SM et al. (1995) Radiation injury to the heart. Int J Radiat Oncol Biol Phys 31:1205–1211

    Article  PubMed  Google Scholar 

  23. Fajardo LF, Stewart JR, Cohn KE (1968) Morphology of radiation-induced heart disease. Arch Pathol 86:512–519

    PubMed  Google Scholar 

  24. Chello M, Mastroroberto P, Romano R et al. (1996) Changes in the proportion of types I and III collagen in the left ventricular wall of patients with post-irradiative pericarditis. Cardiovasc Surg 4:222–226

    Article  PubMed  Google Scholar 

  25. McEniery PT, Dorosti K, Schiavone W et al. (1987) Clinical and angiographic features of coronary artery disease after chest irradiation. Am J Card 60:1020–1024

    Article  PubMed  Google Scholar 

  26. King V, Constine LS, Clark D et al. (1996) Symptomatic coronary artery disease after mantle irradiation for Hodgkin's disease. Int J Radiat Oncol Biol Phys 36:881–889

    Article  PubMed  Google Scholar 

  27. Veinot JP, Edwards WD (1996) Pathology of radiation-induced heart disease: a surgical and autopsy study of 27 cases. Hum Pathol 27:766–773

    Article  PubMed  Google Scholar 

  28. Fajardo LF (1977) Radiation-induced coronary artery disease. Chest 71:563–564

    PubMed  Google Scholar 

  29. Corn BW, Trock B, Goodman R (1990) Irradiation-related ischemic heart disease. J Clin Oncol 8:741–750

    PubMed  Google Scholar 

  30. Adams MJ, Lipshultz SE, Schwartz C et al. (2003) Radiation-associated cardiovascular disease: manifestations and management. Semin Radiat Oncol 13:346–356

    Article  PubMed  Google Scholar 

  31. Brosius FC, Waller BF, Roberts WC (1981) Radiation heart disease. Analysis of 16 young (aged 15–33 years) necropsy patients who received over 3,500 rads to the heart. Am J Med 70:519–530

    Article  PubMed  Google Scholar 

  32. Carlson RG, Mayfield W, Normann S et al. (1991) Radiation-associated valvular disease. Chest 99:538–545

    PubMed  Google Scholar 

  33. Steinherz LJ, Wexler LH (1998) The prevention of anthracycline cardiomyopathy. Prog Pediatr Cardiol 8:97–108

    Article  Google Scholar 

  34. Jemal A, Thomas A, Murray T et al. (2002) Cancer statistics. CA 52:23–47

    PubMed  Google Scholar 

  35. Krischer JP, Epstein S, Cuthbertson DD et al. (1997) Clinical cardiotoxicity following anthracycline treatment for childhood cancer: the Pediatric Oncology Group. J Clin Oncol 15:1544–1552

    PubMed  Google Scholar 

  36. Giantris A, Abdurrahman L, Hinkle A et al. (1998) Anthracycline-induced cardiotoxicity in children and young adults. Crit Rev Oncol Hematol 27:53–68

    PubMed  Google Scholar 

  37. Von Hoff DD, Layard MW, Basa P et al. (1979) Risk factors for doxorubicin-induced congestive heart failure. Ann Intern Med 91:710–717

    PubMed  Google Scholar 

  38. Praga C, Beretta G, Vigo PL et al. (1979) Adriamycin cardiotoxicity: a survey of 1273 patients. Cancer Trt Rep 63:827–834

    Google Scholar 

  39. Lipshultz SE, Sallan SE (1993) Cardiovascular abnormalities in long-term survivors of childhood malignancy. J Clin Oncol 11:1199–1203

    PubMed  Google Scholar 

  40. Lipshultz SE, Sanders SP, Goorin A (1994) Monitoring for anthracycline cardiotoxicity. Pediatrics 93:433–437

    PubMed  Google Scholar 

  41. Lefrak EA, Pitha J, Rosenheim S et al. (1973) A clinicopathologic analysis of adriamycin toxicity. Cancer 32:302–314

    PubMed  Google Scholar 

  42. Grenier MA, Lipshultz SE (1998) Epidemiology of anthracycline cardiotoxicity in children and adults. Semin Oncol 25:72–85

    PubMed  Google Scholar 

  43. Steinherz LJ, Steinherz PG, Tan CT et al. (1991) Cardiac toxicity 4 to 20 years after completing anthracycline therapy. JAMA 266:1672–1677

    Article  PubMed  Google Scholar 

  44. Ali MK, Ewer MS, Gibbs HR et al. (1994) Late doxorubicin-associated cardiotoxicity in children: the possible role of intercurrent viral infection. Cancer 74:182–188

    PubMed  Google Scholar 

  45. Steinherz LJ, Steinherz PG, Tan G (1995) Cardiac failure and dysrhythmias 6–19 years after anthracycline therapy: a series of 15 patients. Med Pediatr Oncol 24:352–361

    PubMed  Google Scholar 

  46. Lipshultz SE, Vlach SA, Lipsitz SR, Sallen SE, Schwartz ML, Colan SD. Cardiac changes associated with growth hormone therapy in children treated with anthracycline. (Pediatrics. In press, 2004)

    Google Scholar 

  47. Davis LE, Brown CE (1988) Peripartum heart failure in a patient treated previously with doxorubicin. Obstet Gynecol 71:506–508 (abstract)

    PubMed  Google Scholar 

  48. Lipshultz SE, Lipsitz SR, Mone SM et al. (1995) Female sex and drug dose as risk factors for late cardiotoxic effects of doxorubicin therapy for childhood cancer. N Engl J Med 332:1738–1743

    Article  PubMed  Google Scholar 

  49. Larsen RL, Barber G, Heise CT et al. (1992) Exercise assessment of cardiac function in children and young adults before and after bone marrow transplantation. Pediatrics 89:722–729

    PubMed  Google Scholar 

  50. Larsen RL, Jakacki RI, Vetter VL et al. (1992) Electrocardiographic changes and arrhythmias after cancer therapy in children and young adults. Am J Cardiol 70:73–77

    Article  PubMed  Google Scholar 

  51. Green DM, Grigoriev YA, Nan B et al. (2001) Congestive heart failure after treatment for Wilms’ Tumor: A report from the National Wilms'Tumor Study Group. J Clin Oncol 19:1926–1934

    PubMed  Google Scholar 

  52. Schwartz CL, Hobbie W, Truesdell S et al. (1993) Corrected QT interval prolongation in anthracycline-treated survivors of childhood cancer. J Clin Oncol 11:1906–1910

    PubMed  Google Scholar 

  53. Jakacki RI, Larsen RL, Barber G, Goldwein JW, Silber JH. Cardiac function following cardiotoxic therapy during childhood assessing the damage. In Cardiac Toxicity after Treatment for Childhood Cancer. Eds. Bricker JT, Green DM, D'Angio GJ. NY, NY: John Wiley & Sons, 1993:87–94

    Google Scholar 

  54. Bender KS et al. (1984) QT interval prolongation associated with anthracycline cardiotoxicity. J Pediatr 105:442–444

    PubMed  Google Scholar 

  55. Bristow MR, Mason JW, Billingham ME et al. (1978) Doxorubicin cardiomyopathy: evaluation by phonocardiography, endomyocardial biopsy and cardiac catheterization. Ann Intern Med 88:168–175

    PubMed  Google Scholar 

  56. Cortes EP, Lutman G, Wanka J et al. (1975) Adriamycin (NSC-123127) cardiotoxicity: a clinicopathologic correlation. Cancer Chemother Rep 6:215–225

    Google Scholar 

  57. Dearth J, Osborn R, Wilson E et al. (1984) Anthracycline-induced cardiomyopathy in children: a report of six cases. Med Pediatr Oncol 12:54–58

    PubMed  Google Scholar 

  58. Von Hoff DD, Rozencweig M, Layard M et al. (1977) Daunomycin-induced cardiotoxicity in children and adults. A review of 110 cases. Am J Med 62:200–208

    Article  PubMed  Google Scholar 

  59. Postma A, Bink-Boelkens MTE, Beaufort-Krol GCM et al. (1996) Late cardiotoxicity after treatment for a malignant bone tumor. Med Pediatr Oncol 26:230–237

    Article  PubMed  Google Scholar 

  60. Nysom K, Holm K, Lipsitz SR et al. (1998) The relation between cumulative anthracycline dose and late cardiotoxicity in survivors of childhood leukemia. J Clin Oncol 16:545–550

    PubMed  Google Scholar 

  61. Silber JH, Jakacki RI, Larsen RL et al. (1993) Increased risk of cardiac dysfunction after anthracyclines in girls. Med Pediatr Oncol 21:477–479

    PubMed  Google Scholar 

  62. Rodvold KA, Rushing DA, Tewksbury DA (1988) Doxorubicin clearance in the obese. J Clin Oncol 6:1321–1327

    PubMed  Google Scholar 

  63. Lipshultz SE, Giantris AL, Lipsitz SR et al. (2002) Doxorubicin administration by continuous infusion is not cardioprotective: the Dana-Farber 91-01 Acute Lymphoblastic Leukemia Protocol. J Clin Oncol 20:1677–1682

    Article  PubMed  Google Scholar 

  64. Levitt GA, Dorup I, Sorenson K, Sullivan I. Does anthracycline administration by infusion in children affect late cardiotoxicity? Brit J Hematol 124:463–468

    Google Scholar 

  65. Krischer JP, Cuthbertson DD, Epstein S et al. (1998) Risk factors for early anthracycline clinical cardiotoxicity in children: the Pediatric Oncology Group experience. Prog Pediatr Cardiol 8:83–90

    Article  Google Scholar 

  66. Pohjola-Sintonen S, Totterman KJ, Kupari M (1990) Sick sinus syndrome as a complication of mediastinal radiation therapy. Cancer 65:2494–2496

    PubMed  Google Scholar 

  67. Adams MJ, Lipsitz SR, Colan SD et al. (2004) Cardiovascular status in long-term survivors of Hodgkin's Disease treated with chest rediotherapy. J Clin Oncol 22:3139–3148

    Article  PubMed  Google Scholar 

  68. Lee CK, Aeppli D, Nierengarten ME (2000) The need for long-term surveillance for patients treated with curative radiotherapy for Hodgkin's disease: University of Minnesota experience. Int J Radiat Oncol Biol Phys 48:169–179

    Article  PubMed  Google Scholar 

  69. Mauch P, Kalish LA, Marcus KC et al. (1995) Long-term survival in Hodgkin's disease: relative impact of mortality, second tumors, infection and cardiovascular disease. Cancer J Sci Am 1:33–42

    PubMed  Google Scholar 

  70. Hancock SL, Tucker MA, Hoppe RT (1993) Factors affecting late mortality from heart disease after treatment for Hodgkin's disease. JAMA 270:1949–1955

    Article  PubMed  Google Scholar 

  71. Hancock SL, Donaldson SS, Hoppe RT (1993) Cardiac disease following treatment of Hodgkin's disease in children and adolescents. J Clin Oncol 11:1208–1215

    PubMed  Google Scholar 

  72. Reinders JG, Heijmen BJ, Olofsen-van Acht MJ et al. (1999) Ischemic heart disease after mantlefield irradiation for Hodgkin's disease in long-term follow-up. Radiother Oncol 51:35–42

    Article  PubMed  Google Scholar 

  73. Glanzmann C, Kaufmann P, Jenni R et al. (1998) Cardiac risk after mediastinal irradiation for Hodgkin's disease. Radiother Oncol 46:51–62

    Article  PubMed  Google Scholar 

  74. Radwaner BA, Geringer B, Goldman AM et al. (1987) Left main coronary artery stenosis following mediastinal irradiation. Am J Med 82:1017–1020

    Article  PubMed  Google Scholar 

  75. Rodgers DL (1976) Precocious myocardial infarction after radiation treatment for Hodgkin's disease. Chest 70:675–677

    PubMed  Google Scholar 

  76. Totterman KJ, Pesonen E, Siltanen P (1983) Radiation related chronic heart disease. Chest 83:875–878

    PubMed  Google Scholar 

  77. Angelini A, Benciolini P, Thiene G (1985) Radiation-induced coronary obstructive atherosclerosis and sudden death in a teenager. Int J Cardiol 9:371–373

    Article  PubMed  Google Scholar 

  78. Boivin J-F, Hutchison G, Lubin J et al. (1992) Coronary artery disease mortality in patients treated for Hodgkin's disease. Cancer 69:1241–1247

    PubMed  Google Scholar 

  79. Pohjola-Sintonen S, Totterman KJ, Salmo M et al. (1987) Late cardiac effects of mediastinal radiotherapy in patients with Hodgkin's disease. Cancer 60:31–37

    PubMed  Google Scholar 

  80. Carmel RJ, Kaplan HS (1976) Mantle irradiation in Hodgkin's disease. Cancer 37:2813–2815

    PubMed  Google Scholar 

  81. Martin RG, Ruckdeschel J, Chang P et al. (1975) Radiationrelated pericarditis. Am J Cardiol 35:216–220

    Article  PubMed  Google Scholar 

  82. Arsenian MA (1991) Cardiovascular sequelae of therapeutic thoracic radiation. Prog Cardiovasc Dis 33:299–311

    Article  PubMed  Google Scholar 

  83. Applefeld MM (1981) The late appearance of chronic pericardial disease in patients treated by radiotherapy for Hodgkin's disease. Ann Intern Med 94:338–341

    PubMed  Google Scholar 

  84. Byhardt R, Brace K, Ruckdeschel JC et al. (1975) Dose and treatment factors in radiation-related pericardial effusion associated with the mantle technique for Hodgkin's disease. Cancer 35:795–802

    PubMed  Google Scholar 

  85. Cameron EH, Lipshultz SE, Tarbell NJ et al. (1998) Cardiovascular disease in long-term survivors of pediatric Hodgkin's disease. Prog Pediatr Cardiol 8:139–144

    Article  Google Scholar 

  86. Tolba KA, Deliargyris EN (1999) Cardiotoxicity of cancer therapy. Cancer Invest 17:408–422

    PubMed  Google Scholar 

  87. Burns RJ, Bar Shlomo BZ, Druck MN et al. (1983) Detection of radiation cardiomyopathy by gated radionuclide angiography. Am J Med 74:297–301

    Article  PubMed  Google Scholar 

  88. Constine LS, Schwartz RG, Savage D et al. (1997) Cardiac function, perfusion, and morbidity in irradiated long-term survivors of Hodgkin's disease. Int J Radiat Oncol Biol Phys 39:897–906

    Article  PubMed  Google Scholar 

  89. Hardenbergh PH, Munley MT, Bentel GC et al. (2001) Cardiac perfusion changes in patients treated for breast cancer with radiation therapy and doxorubicin: preliminary results. Int J Radiat Oncol Biol Phys 49:1023–1028

    Article  PubMed  Google Scholar 

  90. Gyenes G, Fornander T, Carlens P et al. (1996) Myocardial damage in breast cancer patients treated with adjuvant radiotherapy: a prospective study. Int J Radiat Oncol Biol Phys 36:899–905

    Article  PubMed  Google Scholar 

  91. Adams MJ, Hardenbergh P, Constine LS et al. (2003) Radiation-associated cardiovascular disease. Crit Rev Oncol Hematol 45:55–75

    PubMed  Google Scholar 

  92. Merrill J, Geco FA, Zimber H et al. (1975) Adriamycin and radiation: synergistic cardiotoxicity. Ann Intern Med 82:122–123 (abstract)

    Google Scholar 

  93. Kinsella TJ, Ahmann DL, Giuliani ER et al. (1979) Adriamycin toxicity in stage IV breast cancer: possible enhancement with prior left chest radiation therapy. Int J Radiat Oncol Biol Phys 5:1979–2002

    Google Scholar 

  94. Fajardo LF, Eltringham JR, Stewart JR (1976) Combined cardiotoxicity of adriamycin and x-radiation. Lab Invest 34:86–96

    PubMed  Google Scholar 

  95. Eltringham JR, Fajardo LF, Stewart JR et al. (1979) Investigation of cardiotoxicity in rabbits from adriamycin and fractionated cardiac irradiation: preliminary results. Front Radiat Ther Oncol 13:21–35

    Google Scholar 

  96. Pihkala J, Saarinen U, Lundstrom U et al. (1996) Myocardial function in children and adolescents after therapy with anthracyclines and chest irradiation. Eur J Cancer 32A:97–103

    Article  PubMed  Google Scholar 

  97. Leonard GT, Green DM, Spangenthal EL et al. (2000) Cardiac mortality and morbidity after treatment for Hodgkin disease during childhood and adolescence. Pediatr Res 47:46A (abstract)

    Google Scholar 

  98. Shapiro CL, Hardenbergh PH, Gelman R et al. (1998) Cardiac effects of adjuvant doxorubicin and radiation therapy in breast cancer patients. J Clin Oncol 16:3493–3501

    PubMed  Google Scholar 

  99. Glanzmann C, Huguenin P, Lutolf UM et al. (1994) Cardiac lesions after mediastinal radiation for Hodgkin's disease. Radiother Oncol 30:43–54

    Article  PubMed  Google Scholar 

  100. Gustavsson A, Eskilsson J, Landberg T et al. (1990) Late cardiac effects after mantle radiation in patients with Hodgkin's disease. Ann Oncol 1:355–363

    PubMed  Google Scholar 

  101. Lund MB, Ihlen H, Voss BM et al. (1996) Increased risk of heart valve regurgitation after mediastinal radiation for Hodgkin's disease: an echocardiographic study. Heart 75:591–595

    PubMed  Google Scholar 

  102. Adams MJ, Lipsitz SR, Colan SD et al. (2004) Cardiovascular status in long-term survivors of Hodgkin's Disease treated with chest rediotherapy. J Clin Oncol 22:3139–3148

    Article  PubMed  Google Scholar 

  103. Orzan F, Brusca A, Gaita F et al. (1993) Associated cardiac lesions in patients with radiation-induced complete heart block. Int J Cardiol 39:151–156

    Article  PubMed  Google Scholar 

  104. Slama MS, Le Guludec D, Sebag C et al. (1991) Complete atrioventricular block following mediastinal irradiation: a report of six cases. PACE 14:1112–1118

    PubMed  Google Scholar 

  105. Hancock SL (1998) Cardiac toxicity after cancer therapy. Research issues in Cancer Survivorship Meeting, 3 Mar 1998. National Cancer Institute, Bethesda, Maryland

    Google Scholar 

  106. Childrens Oncology Group (2004) Long-term follow-up guidelines for survivors of childhood, adolescent, and young adult cancers. http://www.survivorshipguidelines.org/. (electronic citation)

    Google Scholar 

  107. Steinherz LJ, Graham T, Hurwitz R et al. (1992) Guidelines for cardiac monitoring of children during and after anthracycline therapy: report of the cardiology committee of the Children's Cancer Study Group. Pediatrics 89:942–949

    PubMed  Google Scholar 

  108. Lipshultz SE, Colan SD (1993) The use of echocardiography and Holter monitoring in the assessment of anthracycline-treated patients, Cardiac Toxicity after Treatment for Childhood Cancer. Wiley-Liss, New York, pp 45–62

    Google Scholar 

  109. Colan SD, Borow KM, Neuman A (1984) Left ventricular end-systolic wall stress-velocity of fiber shortening relation: a load independent index of myocardial contractility. J Am Coll Cardiol 4:715–724

    PubMed  Google Scholar 

  110. Weesner KM (1991) Exercise echocardiography in the detection of anthracycline cardiotoxicity. Cancer 68:435–438

    PubMed  Google Scholar 

  111. Mancini DM, Eisen H, Kussmaul W et al. (1991) Value of peak exercise oxygen consumption for the optimal timing of cardiac transplantation in ambulatory patients with heart failure. Circulation 83:778–786

    PubMed  Google Scholar 

  112. Orzan F, Brusca A, Conte MR et al. (1993) Severe coronary artery disease after radiation therapy of the chest and mediastinum: clinical presentation and treatment. Br Heart J 69:496–500

    PubMed  Google Scholar 

  113. Adams MJ, Constine LS, Lipshultz SE (2001) Radiation. In: Crawford MH, DiMarco JP (eds) Cardiology. Mosby International, London, pp 8.15.1–8

    Google Scholar 

  114. Speyer JL, Green MD, Kramer E et al. (1988) Protective effect of the bispiperazinedione ICRF-187 against doxorubicin-induced cardiac toxicity in women with advanced breast cancer. N Engl J Med 319:745–752

    PubMed  Google Scholar 

  115. Swain SM, Whaley FS, Gerber MC et al. (1997) Cardioprotection with dexrazoxane for doxorubicin-containing therapy in advanced breast cancer. J Clin Oncol 15:1318–1332

    PubMed  Google Scholar 

  116. Speyer JL, Green MD, Zeleniuch-Jacquotte A et al. (1992) ICRF-187 permits longer treatment with doxorubicin in women with breast cancer. J Clin Oncol 10:117–127

    PubMed  Google Scholar 

  117. Bu'Lock FA, Gabriel HM, Oakhill A et al. (1993) Cardioprotection by ICRF187 against high dose anthracycline toxicity in children with malignant disease. Br Heart J 70:185–188

    PubMed  Google Scholar 

  118. Wexler LH, Andrich MP, Venzon D et al. (1996) Randomized trial of the cardioprotective agent ICRF-187 in pediatric sarcoma patients treated with doxorubicin. J Clin Oncol 14:362–372

    PubMed  Google Scholar 

  119. Lipshultz SE, Rifai N, Dalton VM et al. (2004) The effect of Dexrazoxane on myocardial injury in doxorubicin-treated children with acute lymphoblastic leukemia. New Engl J Med 2004; 351:145–153

    Article  PubMed  Google Scholar 

  120. Schwartz CL, Tebbi CK, London WB et al. (2003) Enhanced toxicity in pediatric Hodgkin disease (HD) patients treated with DBVE or DBVE-PC and Dexrazoxane (DXR). Blood 102:11–16 (abstract)

    Article  Google Scholar 

  121. Hinkle AS, Truesdell SC, Proukou CB et al. (1998) Cardiotoxicity related to cancer therapy. Prog Pediatr Cardiol 8:145–155

    Article  Google Scholar 

  122. Heart Failure Guideline Panel (1994) Heart Failure: evaluation and care of patients with left ventricular systolic dysfunction. Clinical Practice Guideline #11. US Department of Health and Human Services, Agency for Health Care Policy and Research (report)

    Google Scholar 

  123. Guidelines for the evaluation and management of heart failure (1995) Report of the American College of Cardiology/American Heart Association Task Force on Practice Guidelines (Committee on Evaluation and Management of Heart Failure). Circulation 92:2764–2784

    Google Scholar 

  124. Hunt SA, Baker DW, Chin MH et al. (2001) ACC/AHA Guidelines for the Evaluation and Management of Chronic Heart Failure in the Adult: Executive Summary A Report of the American College of Cardiology/American Heart Association Task Force on Practice Guidelines (Committee to Revise the 1995 Guidelines for the Evaluation and Management of Heart Failure): developed in Collaboration With the International Society for Heart and Lung Transplantation; endorsed by the Heart Failure Society of America. Circulation 104:2996–3007

    PubMed  Google Scholar 

  125. Miller TL, Horgan S, Lipshultz SE. Exercise rehabilitation of pediatric patients with cardiovascular disease. Prog Pediatr Cardiol. (In press 2004)

    Google Scholar 

  126. Expert Panel on Detection, Evaluation, And Treatment of High Blood Cholesterol In Adults (2001) Executive Summary of The Third Report of The National Cholesterol Education Program (NCEP) Expert Panel on Detection, Evaluation, And Treatment of High Blood Cholesterol In Adults (Adult Treatment Panel III). JAMA 285:2486–2497

    Google Scholar 

  127. Lipshultz SE, Lipsitz SR, Sallan SE et al. (2003) Treatment for asymptomatic anthracycline-induced cardiac dysfunction in childhood cancer survivors: the need for evidence: in reply (letter). J Clin Oncol 21:3377–3378

    Article  PubMed  Google Scholar 

  128. Lipshultz SE, Colan SD (2004) Cardiovascular trials in long-term survivors of childhood cancer. J Clin Oncol 22:769–773

    Article  PubMed  Google Scholar 

  129. Pitt B, Zannad F, Remme WJ et al. (1999) The effect of spironolactone on morbidity and mortality in patients with severe heart failure. Randomized Aldactone Evaluation Study Investigators (comment). N Engl J Med 341:709–717

    Article  PubMed  Google Scholar 

  130. Noori A, Lindenfield J, Wolfel E et al. (2000) Beta-blockade in adriamycin-induced cardiomyopathy. J Cardiac Failure 6:115–119

    Google Scholar 

  131. Pfeffer MA, Braunwald E, Moye LA et al. (1992) Effect of captopril on mortality and morbidity in patients with left ventricular dysfunction after myocardial infarction. Results of the survival and ventricular enlargement trial. The SAVE Investigators. N Engl J Med 327:669–677

    PubMed  Google Scholar 

  132. Lipshultz SE, Lipsitz SR, Sallan SE et al. (2002) Long-term enalapril therapy for left ventricular dysfunction in doxorubicin-treated survivors of childhood cancer. J Clin Oncol 20:4517–4522

    Article  PubMed  Google Scholar 

  133. Packer M, Bristow MR, Cohn JN et al. (1996) The effect of carvedilol on morbidity and mortality in patients with chronic heart failure. N Engl J Med 334:1349–1355

    Article  PubMed  Google Scholar 

  134. Woodley SL, Gilbert EM, Anderson JL et al. (1991) Beta-blockade with bucindolol in heart failure caused by ischemic versus idiopathic dilated cardiomyopathy. Circulation 84:2426–2441

    PubMed  Google Scholar 

  135. Fisher ML, Gottlieb SS, Plotnick GD et al. (1994) Beneficial effects of metoprolol in heart failure associated with coronary artery disease: a randomized trial. J Am Coll Cardiol 23:843–950

    Google Scholar 

  136. Olsen SL, Gilbert EM, Renlund DG et al. (1995) Carvedilol improves left ventricular function and symptoms in chronic heart failure: a double-blind randomized study. J Am Col Cardiol 25:1225–1231

    Article  Google Scholar 

  137. Waagstein F, Bristow MR, Swedberg K (1993) Beneficial effects of metoprolol in idiopathic dilated cardiomyopathy. Lancet 342:1441–1446

    Article  PubMed  Google Scholar 

  138. Dillon TA, Sullivan M, Schatzlein MH et al. (1991) Cardiac transplantation in patients with preexisting malignancies. Transplantation 52:82–85

    PubMed  Google Scholar 

  139. Stevenson LW, Warner SL, Steimle AE et al. (1994) The impending crisis awaiting cardiac transplantation. Modeling a solution based on selection. Circulation 89:450–457

    PubMed  Google Scholar 

  140. Herman EH, Zhang J, Lipshultz SE et al. (1999) Correlation between serum levels of cardiac troponin-T and the severity of chronic cardiomyopathy induced by doxorubicin. J Clin Oncol 17:2237–2243

    PubMed  Google Scholar 

  141. Hicks GL Jr (1992) Coronary artery operation in radiation-associated atherosclerosis: long-term follow-up. Ann Thorac Surg 53:670–674

    PubMed  Google Scholar 

  142. Gharagozloo F, Clements I, Mullany C (1992) Use of the internal mammary artery for myocardial revascularization in a patient with radiation-induced coronary artery disease. Mayo Clin Proc 67:1081–1084

    PubMed  Google Scholar 

  143. Handa N, McGregor CG, Danielson GK et al. (1999) Coronary artery bypass grafting in patients with previous mediastinal radiation therapy. J Thorac Cardiovasc Surg 117:1136–1142

    PubMed  Google Scholar 

  144. Van Son JA, Noyez L, van Asten W (1992) Use of internal mammary artery in myocardial revascularization after mediastinal irradiation. J Thorac Cardiovasc Surg 104:1539–1544

    PubMed  Google Scholar 

  145. Reber D, Birnbaum DE, Tollenaere P (1995) Heart diseases following mediastinal irradiation: surgical management. Eur J Cardiothorac Surg 9:202–205

    Article  PubMed  Google Scholar 

  146. Mittal S, Berko B, Bavaria J et al. (1996) Radiation-induced cardiovascular dysfunction. Am J Cardiol 78:114–115

    Article  PubMed  Google Scholar 

  147. Morton DL, Glancy D, Joseph WL et al. (1973) Management of patients with radiation-induced pericarditis with effusion: a note on the development of regurgiation in two of them. Chest 64:291–297

    PubMed  Google Scholar 

  148. Huettemann E, Junker T, Chatzinikolaou KP et al. (2004) The influence of anthracycline therapy on cardiac function during anesthesia. Anesth Analg 98:941–947

    Article  PubMed  Google Scholar 

  149. Kodama K, Fujiwara S, Yamada M et al. (1996) Profiles of non-cancer disease in atomic bomb survivors. World Health Statistics Quarterly-Rapport Trimestriel de Statistiques Saintaires Mondiales 49:7–16

    Google Scholar 

  150. Warda M, Khan A, Massumi A et al. (1983) Radiation-induced valvular dysfunction. J Am Coll Cardiol 2:180–185

    PubMed  Google Scholar 

  151. Shimizu Y, Kato H, Schull W et al. (1992) Studies of mortality of A-bomb survivors: mortality 1950–1985, part 3. Non-cancer mortality based on the revised doses. Radiat Res 130:249–266

    PubMed  Google Scholar 

  152. Shimizu Y, Pierce DA, Preston DL et al. (1999) Studies of mortality of atomic bomb survivors, report 12, part II. Non-cancer mortality: 1950–1990. Radiat Res 152:374–389

    PubMed  Google Scholar 

  153. Perrault DJ, Levy M, Herman JD et al. (1985) Echocardiographic abnormalities following cardiac radiation. J Clin Oncol 3:546–551

    PubMed  Google Scholar 

  154. Heidenreich PA, Hancock SL, Lee BK, Mariscal CS, Schnittger I. Asymptomatic cardiac disease following mediastinal irradiation. J Am Col Cardiol 2003; 42:743–749

    Article  Google Scholar 

Download references

Authors
  1. M. Jacob Adams
    View author publications

    You can also search for this author in PubMed Google Scholar

  2. Sarah A. Duffy
    View author publications

    You can also search for this author in PubMed Google Scholar

  3. Louis S. Constine
    View author publications

    You can also search for this author in PubMed Google Scholar

  4. Steven E. Lipshultz
    View author publications

    You can also search for this author in PubMed Google Scholar

Editor information

Editors and Affiliations

  1. The Sidney Kimmel Cancer Center at Johns Hopkins, Johns Hopkins Hospital, 600 North Wolfe Street, Baltimore, MD, 21287-5001, USA

    Cindy L. Schwartz

  2. Division of Oncology, Childrens Hospital of Philadelphia, 34th St. & Civic Ctr. Blvd., Philadelphia, PA, 19104, USA

    Wendy L. Hobbie

  3. Radiation Oncology and Pediatrics, University of Rochester Medical Center, 601 Elmwood Avenue, Box 647, Rochester, NY, 14642, USA

    Louis S. Constine

  4. Center for Cancer and Blood Diseases, Childrens Hospital Los Angeles, 4650 Sunset Boulevard, Los Angeles, CA, 90027, USA

    Kathleen S. Ruccione

Rights and permissions

Reprints and permissions

Copyright information

© 2005 Springer-Verlag Berlin Heidelberg

About this chapter

Cite this chapter

Adams, M.J., Duffy, S.A., Constine, L.S., Lipshultz, S.E. (2005). Cardiovascular Effects of Cancer Therapy. In: Schwartz, C.L., Hobbie, W.L., Constine, L.S., Ruccione, K.S. (eds) Survivors of Childhood and Adolescent Cancer. Pediatric Oncology. Springer, Berlin, Heidelberg. https://doi.org/10.1007/3-540-26498-1_10

Download citation

  • DOI: https://doi.org/10.1007/3-540-26498-1_10

  • Publisher Name: Springer, Berlin, Heidelberg

  • Print ISBN: 978-3-540-40840-6

  • Online ISBN: 978-3-540-26498-9

  • eBook Packages: MedicineMedicine (R0)

Publish with us

Policies and ethics

Search

Navigation